These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34726348)

  • 1. Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
    Boada M; López OL; Olazarán J; Núñez L; Pfeffer M; Puente O; Piñol-Ripoll G; Gámez JE; Anaya F; Kiprov D; Alegret M; Grifols C; Barceló M; Bozzo J; Szczepiorkowski ZM; Páez A;
    Alzheimers Dement; 2022 Jul; 18(7):1314-1324. PubMed ID: 34726348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
    Boada M; López OL; Olazarán J; Núñez L; Pfeffer M; Paricio M; Lorites J; Piñol-Ripoll G; Gámez JE; Anaya F; Kiprov D; Lima J; Grifols C; Torres M; Costa M; Bozzo J; Szczepiorkowski ZM; Hendrix S; Páez A
    Alzheimers Dement; 2020 Oct; 16(10):1412-1425. PubMed ID: 32715623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study.
    Cuberas-Borrós G; Roca I; Castell-Conesa J; Núñez L; Boada M; López OL; Grifols C; Barceló M; Pareto D; Páez A
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4589-4600. PubMed ID: 35867135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study.
    Boada M; Kiprov D; Anaya F; López OL; Núñez L; Olazarán J; Lima J; Grifols C; Barceló M; Rohe R; Prieto-Fernández C; Szczepiorkowski ZM; Páez A
    J Clin Apher; 2023 Feb; 38(1):45-54. PubMed ID: 36305459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study.
    Grifols C; Barceló M; Núñez L; Szczepiorkowski ZM; Boada M; López OL; Páez A
    Ther Apher Dial; 2023 Oct; 27(5):949-959. PubMed ID: 37211527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.
    Boada M; Anaya F; Ortiz P; Olazarán J; Shua-Haim JR; Obisesan TO; Hernández I; Muñoz J; Buendia M; Alegret M; Lafuente A; Tárraga L; Núñez L; Torres M; Grifols JR; Ferrer I; Lopez OL; Páez A
    J Alzheimers Dis; 2017; 56(1):129-143. PubMed ID: 27911295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.
    Boada M; Ramos-Fernández E; Guivernau B; Muñoz FJ; Costa M; Ortiz AM; Jorquera JI; Núñez L; Torres M; Páez A
    Neurologia; 2016 Sep; 31(7):473-81. PubMed ID: 25023458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin.
    Cuberas-Borrós G; Roca I; Boada M; Tárraga L; Hernández I; Buendia M; Rubio L; Torres G; Bittini Á; Guzmán-de-Villoria JA; Pujadas F; Torres M; Núñez L; Castell J; Páez A
    J Alzheimers Dis; 2018; 61(1):321-332. PubMed ID: 29154283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress.
    Boada M; López O; Núñez L; Szczepiorkowski ZM; Torres M; Grifols C; Páez A
    Alzheimers Dement (N Y); 2019; 5():61-69. PubMed ID: 30859122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease.
    Boada M; Martínez-Lage P; Serrano-Castro P; Costa M; Páez A
    Expert Rev Neurother; 2021 Aug; 21(8):843-849. PubMed ID: 34338566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMBAR, an Encouraging Alzheimer's Trial That Raises Questions.
    Loeffler DA
    Front Neurol; 2020; 11():459. PubMed ID: 32547478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management.
    Costa M; Páez A
    Transfus Apher Sci; 2021 Jun; 60(3):103164. PubMed ID: 34083161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization.
    Boada M; Ortiz P; Anaya F; Hernández I; Muñoz J; Núñez L; Olazarán J; Roca I; Cuberas G; Tárraga L; Buendia M; Pla RP; Ferrer I; Páez A
    Drug News Perspect; 2009; 22(6):325-39. PubMed ID: 19771322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease].
    Boada-Rovira M
    Rev Neurol; 2010 Mar; 50 Suppl 5():S9-18. PubMed ID: 20517868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale.
    Matsui T; Nakaaki S; Murata Y; Sato J; Shinagawa Y; Tatsumi H; Furukawa TA
    Dement Geriatr Cogn Disord; 2006; 21(3):182-91. PubMed ID: 16401890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Exchange in Alzheimer's Disease.
    Rohrer L; Yunce M; Montine TJ; Shan H
    Transfus Med Rev; 2023 Jan; 37(1):10-15. PubMed ID: 36357257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Life in relation to neuropsychiatric symptoms in Alzheimer's disease: 5-year prospective ALSOVA cohort study.
    Hongisto K; Hallikainen I; Selander T; Törmälehto S; Väätäinen S; Martikainen J; Välimäki T; Hartikainen S; Suhonen J; Koivisto AM
    Int J Geriatr Psychiatry; 2018 Jan; 33(1):47-57. PubMed ID: 28067961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive activity for the treatment of older adults with mild Alzheimer's disease (AD)--PACE AD: study protocol for a randomised controlled trial.
    Vidovich MR; Shaw J; Flicker L; Almeida OP
    Trials; 2011 Feb; 12():47. PubMed ID: 21329501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.